Movement disorders associated with the serotonin selective reuptake inhibitors

Journal of Clinical Psychiatry

Volumn 57, Issue 10, 1996, Pages 449-454

  Leo, Raphael J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; AKATHISIA; ARTICLE; DOPAMINERGIC SYSTEM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

EID: 0029806639     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v57n1002     Document Type: Article

References (86)

1. Segraves RT. Sexual side effects of psychiatric drugs. Int J Psychiatry Med 1988;18:243-252
2. Herman JB, Brotman AW, Pollack MH, et al. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990;51:25-27
3. Zajecka J, Fawcett J, Schaff M, et al. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991;52:66-68
4. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55: 406-413
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:735-751
6. Koller W, Musa M. Amitriptyline-induced abnormal movements [letter]. Neurology 1985;35:1086
7. Yassa R, Camille Y, Belzile L. Tardive dyskinesia in the course of antidepressant therapy: a prevalence study and review of the literature. J Clin Psychopharmacol 1987;7:243-246
8. Zubenko GS, Cohen BM, Lipinski JF. Antidepressant-related akathisia. J Clin Psychopharmacol 1987;7:254-257
9. Ornadel D, Barnes EA, Dick DJ. Acute dystonia due to amitriptyline [letter]. J Neurol Neurosurg Psychiatry 1992;55:414
10. Gersten SP. Tardive dyskinesia-like syndromes with clomipramine [letter]. Am J Psychiatry 1993;150:165-166
11. Sabaawi M, Richmond DR, Fragala MR. Akathisia in association with nortriptyline therapy. Am Fam Physician 1993;48:1024-1026
12. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995;152:122-125
13. Choo V. Paroxetine and extrapyramidal reactions [letter]. Lancet 1993; 341:624
14. Meltzer HY, Young M, Metz J, et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979;45:165-175
15. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects [letter]. Am J Psychiatry 1989;146:1352-1353
16. Brod TM. Fluoxetine and extrapyramidal side effects [letter]. Am J Psychiatry 1989;146:1353
17. Lipinski JF Jr, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989;50: 339-342
18. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine [letter]. Am J Psychiatry 1989;146:399-400
19. Austin LS, Arana GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. J Clin Psychiatry 1990;51:344-345
20. Reccoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine [letter]. J Clin Psychiatry 1990;51:487
21. Baldwin D, Fineberg N, Montgomery S. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991;6:51-58
22. Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine [letter]. Am J Psychiatry 1991;148:1403
23. Fallon BA, Liebowitz MR. Fluoxetine and extrapyramidal symptoms in CNS lupus. J Clin Psychopharmacol 1991;11:147-148
24. Fleischhacker WW. Propranolol for fluoxetine-induced akathisia [letter]. Biol Psychiatry 1991;30:531-532
25. Gernaat HBPE, Van de Woude J, Touw DJ. Fluoxetine and parkinsonism in patients taking carbamazepine [letter]. Am J Psychiatry 1991;148: 1604-1605
26. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991; 52:491-493
27. Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine [letter]. Am J Psychiatry 1991;148:683
28. Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine [letter]. Am J Psychiatry 1991;148:1263
29. Black B, Uhde TW. Acute dystonia and fluoxetine [letter]. J Clin Psychiatry 1992;53:327
30. Fishbain DA, Dominguez M, Goldberg M, et al. Dyskinesia associated with fluoxetine use. Neuropsychiatry, Neuropsychology, Behavioral Neurology 1992;5:97-100
31. Hamilton MS, Opler LA. Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 1992;53:401-406
32. Wils V. Extrapyramidal symptoms in a patient treated with fluvoxamine [letter]. J Neurol Neurosurg Psychiatry 1992;55:330-331
33. Wirshing WC, Van Putten T, Rosenberg J, et al. Fluoxetine, akathisia and suicidality: is there a causal connection? [letter] Arch Gen Psychiatry 1992;49:580-581
34. Arya DK, Szabadi E. Dyskinesia associated with fluvoxamine [letter]. J Clin Psychopharmacol 1993;13:365-366
35. George MS, Trimble MR. Dystonic reaction associated with fluvoxamine [letter]. J Clin Psychopharmacol 1993;13:220-221
36. Ketai R. Interaction between fluoxetine and neuroleptics [letter]. Am J Psychiatry 1993;150:836-837
37. Klee B, Kronig MH. Case report of probable sertraline-induced akathisia [letter]. Am J Psychiatry 1993;150:986-987
38. LaPorta LD. Sertraline-induced akathisia [letter]. J Clin Psychopharmacol 1993;13:219-220
39. Lavin MR, Mendelowitz A, Block SH. Adverse reaction to high-dose fluoxetine [letter]. J Clin Psychopharmacol 1993;13:452-453
40. Settle EC Jr. Akathisia and sertraline [letter]. J Clin Psychiatry 1993; 54:321
41. Altshuler LL, Pierre JM, Wirshing WC, et al. Sertraline and akathisia [letter]. J Clin Psychopharmacol 1994;14:278-279
42. Dave M. Fluoxetine-associated dystonia [letter]. Am J Psychiatry 1994; 151:149
43. Lauterbach EC. Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease. Mov Disord 1994;9:343-346
44. Mander A, McCausland M, Workman B, et al. Fluoxetine induced dyskinesia. Aust N Z J Psychiatry 1994;28:328-330
45. Opler LA. Sertraline and akathisia [letter]. Am J Psychiatry 1994;151: 620-621
46. Shihabuddin L, Rapport D. Sertraline and extrapyramidal side effects [letter]. Am J Psychiatry 1994;151:288
47. Adler LA, Angrist BM. Paroxetine and akathisia. Biol Psychiatry 1995; 37:336-337
48. Al-Adwani A. Brain damage and tardive dyskinesia [letter]. Br J Psychiatry 1995;167:410-411
49. Chong SA. Fluvoxamine and mandibular dystonia [letter]. Can J Psychiatry 1995;40:430-431
50. Hoaken PCS. An alert to extrapyramidal side-effects from SSRI's [letter]. Can J Psychiatry 1995;40:51
51. Leo RJ, Lichter DG, Hershey LA. Parkinsonism associated with fluoxetine and cimetidine: a case report. J Geriatr Psychiatry Neurol 1995;8: 231-233
52. Poyurovsky M, Meerovich I, Weizman A. Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. Int Clin Psychopharmacol 1995;10:111-114
53. Baldassano CF, Truman CJ, Nierenberg A, et al. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry 1996;37: 122-124
54. Sandler NH. Tardive dyskinesia associated with fluoxetine [letter]. J Clin Psychiatry 1996;57:91
55. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985;46(3, sec 2):59-67
56. Maany I, Dhopesh V. Akathisia and fluoxetine [letter]. J Clin Psychiatry 1990;51:210
57. Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics; 1996
58. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992;53:278-282
59. Chouinard G, Sultan S. A case of Parkinson's disease exacerbated by fluoxetine. Human Psychopharmacology 1992;7:63-66
60. Jansen ENH, Kolling P. Parkinsonism and fluoxetine [letter]. Ned Tijdschr Geneeskd 1992;136:755-756
61. Steur ENHJ. Increase of Parkinson disability after fluoxetine medication. Neurology 1993;43:211-213
62. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, et al. Parkinsonism exacerbated by paroxetine. Neurology 1994;44:2406
63. Meco G, Bonifati V, Fabrizio E, et al. Worsening of parkinsonism with fluvoxamine: two cases. Human Psychopharmacology 1994;9:439-441
64. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994;55:394-400
65. Dray A. Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. J Physiol (Paris) 1981;77:393-403
66. Azmitia EC. The serotonergic-producing neurons of the midbrain median and dorsal raphe nuclei. In: Iversen LL, Iversen SD, Snyder SH, eds. Handbook of Psychopharmacology, vol 9: Chemical Pathways in the Brain. New York, NY: Plenum Press; 1978:233-314
67. Frisco S, Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol 1995;116:1923-1931
68. Davies J, Tonogroach P. Neuropharmacologic studies on the nigro-striatal and raphe-striatal system in the rat. Eur J Pharmacol 1978;51:91-100
69. Hesselink JMK. Serotonin, depression, and Parkinson's disease [letter]. Neurology 1993;43:1624-1625
70. Meerwaldt JD. Treatment of hypokinetic rigid syndrome with fluvoxamine maleate [letter]. Lancet 1986;1:977-978
71. Durif F, Vidailhet M, Bonnet AM, et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-1858
72. Schreiber S, Pick CG. Fluoxetine for blepharospasm: interaction of serotonin and dopamine. J Nerv Ment Dis 1995;183:719-721
73. Fibiger HC, Lloyd KG. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 1984;7:462-464
74. Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139-150
75. Koe BK, Weissman A, Welch WM, et al. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983; 226:686-700
76. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029
77. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55(9, suppl A):34-39
78. Shank RP, Vaught JL, Pelley KA, et al. McN-5652: a highly potent inhibitor of serotonin uptake. J Pharmacol Exp Ther 1988;247:1032-1038
79. Goff DC, Midha KK, Brotman AW, et al. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991;148:790-792
80. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions, I: antidepressants and antipsychotics. J Clin Psychopharmacol 1990;10:48-50
81. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions, II. J Clin Psychopharmacol 1990;10:213-217
82. Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10-15
83. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Cytochromes in psychopharmacology. J Clin Psychopharmacol 1994;14:1-4
84. Weissman MW, Klerman GL. Sex differences and the epidemiology of depression. Arch Gen Psychiatry 1977;34:98-111
85. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992:149:443-454
86. Montastruc JL, Fabre N, Blin O, et al. Does fluoxetine aggravate Parkinson's disease? a pilot prospective trial [abstract]. Mov Disord 1994;9(1, suppl):99